TB-500: The Fragment Is Not the Whole Protein

FDA's 2026 assessment defines TB-500 as a synthetic N-terminally acetylated, seven-amino-acid fragment containing LKKTETQ, corresponding to residues within thymosin beta-4. The acetyl modification is part of the evaluated substance's identity. ^[3]

Full-length thymosin beta-4 is a 43-amino-acid peptide. It and TB-500 are not the same substance, even though websites and some discussions use their names interchangeably. ^{[3, 9]}

TB-500 free base and TB-500 acetate are distinct active pharmaceutical ingredients. FDA found inconsistent names, identifiers, formulas, and certificate information in the nomination and marketplace, so the short name alone may not identify the material. ^{[3, 2]}

Calling TB-500 a “synthetic version” of the body's thymosin beta-4 obscures a major structural distinction. Evidence for the parent protein should not be assigned to the fragment without direct bridging evidence. ^[3]

The LKKTETQ sequence lies within an actin-binding region of thymosin beta-4. Cell migration, angiogenesis, extracellular-matrix response, and wound repair are therefore recurring mechanistic themes in the literature. ^{[3, 8]}

FDA found broad promotion for injury recovery, wound repair, inflammation, flexibility, mobility, scarring, collagen, and other outcomes. These claims exceed the direct human evidence for TB-500, which FDA did not identify. ^[3]

Sharing a core amino-acid sequence is not enough to establish the same pharmacology. Acetylation can irreversibly alter charge, hydrophobicity, size, folding, lifespan, and binding properties. ^[3]

FDA found no clinical studies or human exposure data using TB-500 by any route and no published human case reports. It also found no medical-literature report in which TB-500 was administered to patients for wound healing or another condition. ^[3]

Human wound studies sometimes cited in this conversation administered full-length thymosin beta-4. Because full-length thymosin beta-4 is not the same substance as TB-500, those human results cannot establish TB-500 efficacy or safety. ^{[9, 3]}

FDA did not identify human pharmacokinetic or pharmacodynamic studies of TB-500. Animal exposure and metabolite findings cannot tell us a person's exposure–response relationship or clinical therapeutic window. ^[3]

The evidence supports neither a claim that TB-500 improves human wound healing nor a precise estimate of its risks. The correct status is unestablished in humans, not “proven by thymosin beta-4 research.” ^{[3, 9]}

A 2003 study reported wound-repair findings in diabetic and aged mice using full-length thymosin beta-4 and an unacetylated LKKTETQ peptide. It was an animal study, and FDA emphasized that the pharmacology of the unacetylated fragment cannot be directly extrapolated to acetylated TB-500. ^{[8, 3]}

FDA identified an in-vitro scratch-wound study in which TB-500 free base did not show wound-healing activity under the reported conditions, while one metabolite showed a signal. A cell result for a metabolite is not a demonstrated organism-level or clinical effect of the parent compound. ^[3]

FDA did not identify nonclinical toxicology studies of TB-500 free base or TB-500 acetate and found the nonclinical pharmacology insufficient to support wound healing. Even before human efficacy, foundational safety questions remain open. ^[3]

Every cited finding should be checked for exact molecule, acetylation, salt form, route, formulation, species, and endpoint. If any of those change, the evidence may no longer support the same claim. ^{[3, 7]}

With no administered-human study identified, the incidence and severity of systemic reactions, interactions, organ toxicity, reproductive or developmental effects, and longer-term harms are unknown. ^[3]

The nomination contemplated injectable products. For any injectable, identity, sterility, bacterial endotoxin control, foreign particulates, potency, and microbiological quality are direct safety issues—not administrative details. ^[3]

FDA identified a potential immunogenicity concern for injectable TB-500, which may be amplified by aggregation and peptide-related impurities. No clinical study assessing TB-500 immunogenicity or aggregation was identified. ^{[3, 6]}

FDA found two surveillance reports involving blended TB-500 and BPC-157, but those reports did not contain safety assessments. Sparse, confounded passive reports cannot establish either causation or reassurance. ^[3]

FDA found important characterization gaps for both evaluated forms, including missing or incomplete controls for impurities, aggregates, microbiological quality, and bacterial endotoxin. A product name cannot compensate for those missing quality data. ^{[3, 4]}

The TB-500 nomination was withdrawn and contained inconsistent information about the free-base and acetate forms. FDA chose to evaluate both substances on its own initiative. ^[3]

The July 2026 review concerned possible 503A Bulks List placement for a nominated wound-healing use. It was a compounding-policy assessment, not an application for FDA approval of a finished drug. ^{[3, 2]}

FDA staff concluded that the physical-chemical characterization, unclear historical compounding use, lack of effectiveness evidence, and absent human safety information weighed against placing both forms on the 503A Bulks List. ^[3]

The Pharmacy Compounding Advisory Committee gives FDA nonbinding advice. Its proceeding is not FDA approval, and a recommendation against list placement is not a statement that TB-500 is banned in every legal or research context. ^{[5, 1]}

FDA's current compounding-risk page includes the thymosin beta-4 fragment known as TB-500 and highlights immunogenicity, aggregation, impurity, and missing-human-data concerns. It is a regulatory risk summary, not a quantified human risk profile. ^[4]

Did the cited study test full-length thymosin beta-4, unacetylated LKKTETQ, acetylated TB-500, a metabolite, the free base, or the acetate—and is that exact identity reflected in the claim? ^{[3, 8, 9]}

Was TB-500 administered to people in a controlled study that measured healing, pain, function, or another patient-important outcome—or is a human claim being inferred from cells, mice, or another molecule? ^[3]

What independent evidence addresses identity, potency, sterility, bacterial endotoxin, particulates, impurities, aggregation, immune risk, and adverse-event monitoring for the finished product? ^{[3, 6]}